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After initial encounter of B cells with antigen, 
their  IgV  genes  are  subjected  to  somatic 
hypermutation (SHM), a process that underpins 
antibody affinity maturation. The isotype of 
the antibody produced can also be altered from 
IgM to IgG, IgA, or IgE by class-switch recom-
bination  (CSR).  Both  SHM  and  CSR  are 
dependent on the protein activation-induced 
deaminase (AID). Although homology of AID 
to the RNA-editing enzyme APOBEC1 led 
to the early suggestion that AID also functioned 
by  editing  RNA  (Muramatsu  et  al.,  2000), 
much evidence indicates that AID functions 
by directly deaminating deoxycytidine residues 
within  the  immunoglobulin  locus  to  yield 
deoxyuridine (Alt and Honjo, 2007; Di Noia 
and Neuberger, 2007). Nevertheless, although 
the supporting evidence is extensive, the DNA 
deamination  mechanism  has  not  gained 
universal acceptance.  There has been discussion 
as to whether the uracil-excision activity of 
uracil-DNA  glycosylase  is  essential  for  its 
function in antibody diversification (Begum 
et al., 2004, 2007, 2009; Stivers, 2004; Nagaoka 
et al., 2005; Di Noia et al., 2007) and, more 
recently, the dependence of antibody diver-
sification on the DNA deaminase activity of AID 
has also been called into question (Shivarov 
et al., 2008).
It has long been known that somatic muta-
tions are not randomly distributed along the 
IgV gene. Although most nucleotide positions 
in the IgV can be targeted during SHM, some 
positions are intrinsically more mutable than 
others, with the SHM process exhibiting a clear 
preference for certain major hotspots (Berek 
and Milstein, 1987; Sharpe et al., 1991; Rogozin 
and  Kolchanov,  1992;  Betz  et  al.,  1993b). 
Thus, for example, a cytosine (C) residue in 
the IgV is especially likely to be mutated during 
SHM if it forms part of a WRCY consensus 
(where W = adenosine/thymine, R = purine, 
and Y = pyrimidine; Rogozin and Kolchanov, 
1992; Betz et al., 1993a; Dörner et al., 1998; 
Milstein et al., 1998; Oprea and Kepler, 1999). 
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High-affinity antibodies are generated by somatic hypermutation with nucleotide substitu-
tions introduced into the IgV in a semirandom fashion, but with intrinsic mutational hot-
spots strategically located to optimize antibody affinity maturation. The process is dependent 
on activation-induced deaminase (AID), an enzyme that can deaminate deoxycytidine in DNA 
in vitro, where its activity is sensitive to the identity of the 5-flanking nucleotide. As a 
critical test of whether such DNA deamination activity underpins antibody diversification 
and to gain insight into the extent to which the antibody mutation spectrum is dependent 
on the intrinsic substrate specificity of AID, we investigated whether it is possible to change 
the IgV mutation spectrum by altering AID’s active site such that it prefers a pyrimidine 
(rather than a purine) flanking the targeted deoxycytidine. Consistent with the DNA deami-
nation mechanism, B cells expressing the modified AID proteins yield altered IgV mutation 
spectra (exhibiting a purine→pyrimidine shift in flanking nucleotide preference) and altered 
hotspots. However, AID-catalyzed deamination of IgV targets in vitro does not yield the 
same degree of hotspot dominance to that observed in vivo, indicating the importance of 
features beyond AID’s active site and DNA local sequence environment in determining  
in vivo hotspot dominance.
© 2010 Wang et al.  This article is distributed under the terms of an Attribution–
Noncommercial–Share Alike–No Mirror Sites license for the first six months 
after the publication date (see http://www.jem.org/misc/terms.shtml). After six 
months it is available under a Creative Commons License (Attribution–Noncom-
mercial–Share Alike 3.0 Unported license, as described at http://creativecommons 
.org/licenses/by-nc-sa/3.0/).
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with an oligonucleotide substrate (Losey et al., 2006), we sug-
gested this amino acid stretch in both AID and APOBEC3s 
likely formed a contact with the DNA substrate (Conticello 
et al., 2007). Thus, to generate AID variants with altered tar-
get specificity, we focused on this stretch of amino acids and 
replaced  AID  residues  115–123  with  the  corresponding 
portion of APOBEC3s (Fig. 1 A). Kohli et al. (2009) have 
recently adopted a similar approach to modify AID’s sub-
strate preference.
Indeed, most of the dominant mutational hotspots within 
IgV genes conform to the WRCY consensus, although not 
all WRCY consensuses form major hotspots. The location of 
these hotspots has been proposed to have been selected dur-
ing evolution because either they are located at positions 
where amino acid substitutions are likely to be particularly 
effective in allowing affinity maturation or they are at codons 
where single-nucleotide substitutions are likely to yield a range 
of potentially useful amino acid substitutions and a reduced 
likelihood  of  generating  stop  codons  (Chang  and  Casali, 
1994; Wagner et al., 1995; Jolly et al., 1996; Kepler, 1997). 
The CDR1 in both VH and VL is a preferred target of somatic 
hypermutation in vivo and is typically rich in AGY serine 
codons, many of which conform well (on the opposite strand) to 
the WRC consensus for AID targets (Betz et al., 1993b; Cowell 
et al., 1999).
Extensive biochemical studies have revealed that when 
acting on a DNA target in vitro recombinant AID also targets 
C residues for deamination in a context-dependent manner 
with  WRC  being  a  favored  consensus  in  single-stranded 
DNA substrates (Pham et al., 2003; Bransteitter et al., 2004; 
Yu et al., 2004; Larijani et al., 2005). Thus, there appears to 
be a broad correlation between the in vitro target preferences 
of AID and the pattern of antibody hotspots in vivo. How-
ever,  comparison  of  mutation  spectra  (albeit  on  different 
DNA target sequences in vivo and in vitro) suggests that the 
two are not identical. Thus, for example, mutational target-
ing in IgV genes appears to show sensitivity to the nucleotide 
flanking the 3-side of the targeted C, whereas such sensitiv-
ity is not apparent from in vitro deamination studies (Pham 
et al., 2003; Beale et al., 2004; Rogozin and Diaz, 2004).
Here, to gain insight into the contribution of the target 
preference of AID’s catalytic site to the overall spectrum of 
antibody hypermutation and as a critical test of the DNA de-
amination mechanism of antibody gene diversification, we 
have generated mutant AIDs with altered sequence prefer-
ences and observed how this affects the spectrum of antibody 
hypermutation.
RESULTS
Active-site mutants of AID
The human APOBEC3 proteins, like AID, are able to deam-
inate C in DNA, but whereas AID prefers to target C resi-
dues flanked by a 5-flanking purine, the APOBEC3s largely 
prefer a 5-pyrimidine flank with individual APOBEC3s dif-
fering with regard to the details of this 5-flanking nucleotide 
preference. Comparison of human APOBEC3 gene sequences 
previously led us to speculate that a stretch of 8 amino acids 
located some 60 residues from the C-terminal end of the 
protein domain played an important role in determining this 
flanking nucleotide preference; we supported this speculation 
by showing that the target specificity of APOBEC3F could 
indeed be altered by specific amino acid changes in this region 
(Langlois et al., 2005). Subsequently, in light of the crystal 
structure of APOBEC2 (Prochnow et al., 2007) together with 
that of the TadA tRNA-adenosine deaminase in complex 
Figure 1.  Changing the target specificity of AID. (A) Depiction of AID 
cDNA showing the Zn coordination domain (HVE and PCYDC), and the re-
gion containing a putative substrate contact loop (gray), with alignment to 
equivalent regions of APOBEC3C, 3F, and 3G shown below. Residues pre-
dicted to be in the substrate contact loop are highlighted in bold. In the AID 
chimeras, residues 115–123 of AID were replaced by equivalent residues in 
APOBEC3C/F/G as indicated. (B) Bacterial mutator activity of variant AIDs 
was determined by the mean frequency from 12 independent cultures with 
which they yielded colonies resistant to rifampicin (Rifr), expressed relative 
to that given by the vector-only control. AID1 and AID2 are previously de-
scribed upmutants of wild-type AID (AID1: K10E/T82I/E156G; AID2: K34E/
E156G/R157T; Wang et al., 2009). (C) Target specificity of the various AID-
derived deaminases as judged by the distribution of rpoB mutations in rifr 
resistant colonies. Transition mutations at any one of eleven C:G pairs 
within rpoB can give rise to Rifr. Mutations at a specific C:G pair are ex-
pressed as a percentage of the total number of Rifr colonies scored for each 
deaminase. Results with AID/3G are shaded black, AID1/3G in dark gray, and 
AID2/3G in light gray (all largely target C1691).JEM VOL. 207, January 18, 2010 
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APOBEC3C/F/G showed a preference (as do the APOBEC3s 
themselves) for pyrimidines at the 1 position. Thus, AID/3C 
and AID/3F show a shift in the spectrum of rpoB mutations 
to favor targets with a 5-T (C1535, C1565, and C1592), 
whereas the AID/3G transformants almost solely targeted 
C1691, which has a 5-C (Fig. 1 C).
Although the mutator activity of AID/3G is sufficient to 
yield a shift in the distribution of rpoB mutations observed in 
rifampicin-resistant E. coli, its mutator activity is nevertheless 
considerably lower than that of the wild-type enzyme because 
it does not yield a total frequency of mutation to rifampicin-
resistance that is above background (Fig. 1). This led us to 
anticipate that it might be difficult to obtain a good database 
of IgV mutations when this AID mutant was expressed in 
B cells. To avoid this problem, we generated two AID/3G 
upmutants (which we designate AID1/3G and AID2/3G) in 
AID mutants in which residues 115–123 had been re-
placed by equivalent regions from APOBEC3C, APOBEC3F, 
and APOBEC3G were cloned into a bacterial expression plas-
mid, and their mutator activity assayed by monitoring the 
frequency  with  which  they  yielded  colonies  resistant  to 
rifampicin  after  transformation  into  E.  coli. Although  the 
AID/3C and AID/3F proteins retained good mutator activity, 
AID/3G gave rifampicin-resistant colonies at a frequency in-
distinguishable over background (Fig. 1 B). Rifampicin resis-
tance is conferred by one of a limited number of mutations in 
rpoB with the nature of the mutations obtained giving insight 
into  the  target  specificity  of  the  deaminase  (Harris  et  al., 
2002). Wild-type AID prefers to deaminate the C residues at 
rpoB position 1576 (C1576), which has a 5-flanking purine 
(G) residue. In contrast, the AID variants in which residues 
115–123 had been replaced by corresponding regions from 
Figure 2.  Mutation spectrum of modified AIDs assayed in vitro on a gapped duplex lacZ target. (A) Depiction of the M13mp19lacZ gapped du-
plex substrate DNA. (B) 5-flanking nucleotide preferences of the C mutations produced by the variant AID deaminases. The spectra shown for the AID/3G 
chimera is from an AID1*/3G derivative in which the asterisk denotes that the protein has been truncated at amino acid position 190 of AID (removing the 
nuclear export sequence) and is shown to allow comparison with the same AID variant analyzed in transfected DT40 B cells (see Fig. 3). The C-terminal 
truncations do not detectably alter the patterns of in vitro mutational targeting. (C) Distribution of mutations over a 310-nt stretch of the single-
stranded lacZ target. The numbers of independent mutations at each nucleotide position are expressed as a percentage of the total mutation database (as 
analyzed over the entire 475-nt single-stranded target). Nucleotide position 1 is defined as the start of the lac promoter. Mutations at C residues flanked 
by a 5-purine (Pu-C) are shown in red, those flanked by a 5-pyrimidine (Py-C) in blue. (D) Identity of the three most frequently targeted residues by 
each deaminase, with targeting expressed as the percentage of clones analyzed in which the relevant cytosine (underlined) was mutated.144 Modifying AID alters IgV mutation spectrum | Wang et al.
Modified AIDs exhibit altered mutation spectra in vitro
To analyze the biochemical target specificity of the mutant 
AIDs in greater detail, the various AID enzymes were par-
tially purified from E. coli extracts as recombinant GST- 
fusion proteins (Fig. S1 A) and used to deaminate single-stranded 
lacZ target DNA in the context of the M13 gapped duplex 
assay (Bebenek and Kunkel, 1995; Pham et al., 2003). In this 
assay,  recombinant  GST-AID  is  incubated  with  gapped 
duplex M13lacZ DNA (Fig. 2 A), which is then trans-
formed into E. coli; white (as opposed to blue) plaques reveal 
mutated clones.
Analysis of 30–50 mutated M13lacZ clones in each ex-
periment  yielded  databases  of  471–685  mutations,  all  of 
which were transitions at C:G pairs (Fig. 2 B). In the case 
of AID1, 74% of the C mutations were at sites flanked by a   
5-purine. In contrast, the AID mutants carrying transplanted 
segments from APOBEC3 proteins showed a shift toward a 
which three additional amino acid substitutions (AID1: K10E, 
T82I, and E156G; AID2: K34E, E156G, and R157T) were 
introduced into these proteins, substitutions that we have 
previously shown to increase AID’s specific activity without 
detectably affecting its target preference (Wang et al., 2009). 
Both these AID/3G upmutants appear to retain the parental 
AID/3G protein’s preference for a 5-flanking C residue as 
judged by the rpoB mutation spectrum (Fig. 1 C).
We also prepared AID variants (designated AID*, AID*/3F, 
AID1*/3G, etc.) in which the C-terminal portion of AID 
(which includes its nuclear export sequence) has been deleted 
because previous work with wild-type AID (Barreto et al., 
2003) has indicated that such deletions could also yield sig-
nificantly increased mutation frequencies in B cell transfec-
tants. The C-terminal truncation does not yield a detectable 
effect on AID mutational target site preference in bacterial 
mutation assays (Fig. S1).
Figure 3.  Modified AIDs give altered IgV hypermutation spectra in B cells. (A) Hypermutation of IgV was assayed by monitoring surface IgM-
loss in AID/ V/ sIgM+ DT40 cells that had been stably transfected with constructs coexpressing the indicated AID mutants together with GFP. For 
each construct, the percentage of surface IgM-loss variants in 8–12 independent clonal transfectants were determined 3 wk after subculturing. On the 
right, Western blots representative of multiple clones show AID abundance in the DT40 cell extracts, with tubulin as loading control. (B) 5-flanking  
nucleotide preferences of the IgV C mutations produced by the variant AID deaminases in the DT40 clonal transfectants. The compilations are based on 
mutations detected in unsorted DT40 cells analyzed 8 wk after transfection, except for AID/3C, where sequences from both unsorted and sorted sIgM 
populations contributed to the mutation database. In the case of AID1*/3G, the nucleotide preferences are given based on an analysis of all the mutations 
in the dataset, as well as from an analysis in which the four major hotspots were removed from the calculations. (C) Percentage of mutated C residues 
flanked by 5-purine (red) or 5-pyrimidine (blue) in IgV sequences analyzed from individual expanded DT40 clonal transfectants represented by each 
bar. (D) Distribution of IgV mutations in the DT40 transfectants, in each comparing the spectrum achieved with a modified AID (below the line) to that 
achieved with wild-type AID (above the line). Mutations (which were >95% at C:G pairs) were computed as being caused by C deamination with those Cs 
flanked by a 5-purine (Pu-C) indicated in red and those by a 5-pyrimidine (Py-C) in blue. Further details on the mutations obtained with these  
deaminases, as well as with AID1 are shown in Fig. S2 and Fig. S3.JEM VOL. 207, January 18, 2010 
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the mutant AIDs in an AID-deficient, V-deleted chicken 
DT40 B cell line. In this cell-line, the mutations are largely 
restricted to nucleotide substitutions at C:G pairs, with little 
contribution  from  polymerase  –triggered  hypermutation 
(Sale et al., 2001; Di Noia and Neuberger, 2002; Arakawa 
et al., 2004), meaning that mutations at C:G can largely be 
ascribed to the direct effects of AID rather than possibly being 
a consequence of a second phase of mutation creation. The 
frequency of SHM at the IgV can be inferred from the fre-
quency of generation of sIgM-loss variants (Buerstedde et al., 
1990; Sale et al., 2001). As judged by this assay, both AID/3C 
and AID/3F are proficient in SHM. Indeed, AID/3C is even 
more potent than the wild-type enzyme, especially when ac-
count is taken of the lower abundance of the AID/3C poly-
peptide in the B cell extracts (Fig. 3 A). The low abundance 
of AID/3C is evident in multiple independent transfectants 
preference for a flanking pyrimidine, especially marked in the 
case of the AID/3C and AID/3G proteins (85 and 77% pyrim-
idine, respectively; Fig. 2 B). This change in flanking nucleo-
tide preference is accompanied by a change in the distribution 
of mutations along lacZ (Fig. 2, C and D). Given that for 
most of the AID variants, the mutated sequences carried an 
average of 10–16 transition mutations over the 475-nt stretch 
of single-stranded substrate analyzed (Fig. S1 B), the muta-
tions observed will largely reflect the intrinsic preference of 
the mutational process without extensive skewing by virtue 
of the selection for lacZ inactivation.
Modified AIDs give altered IgV mutation spectra in B cells
To  ascertain  whether  changing  the  catalytic  specificity  of 
AID results in an alteration in the distribution of nucleotide 
substitutions introduced during SHM in B cells, we expressed 
Figure 4.  Different IgV hotspots dominate the mutation spectra in B cells and in the gapped duplex assay. (A) The M13mp19-IgV-lacZ 
gapped duplex substrate DNA is depicted with more detailed information provided in Fig. S5 A. Nucleotide position 1 is equivalent to the first nucleotide 
of the in vivo IgV analyzed in Fig. 3. (B) The graphs compare the distribution of IgV mutations obtained with AID1 or AID1*/3G in the gapped duplex 
assay (shown below the line) with the distribution of IgV top strand C mutations obtained with the same deaminases in DT40 B cells (shown above the 
line). The distributions of IgV top strand C mutations in DT40 cells for AID1*/3G and AID1 derive from the same mutation databases used in Fig. 3 and  
Fig. S2, respectively, although those figures portray all C mutations (i.e., whichever DNA strand they have occurred upon). The positions of some individual 
hotspots are indicated in italics. Red, 5-purine flank (Pu-C); blue, 5-pyrimidine flank (Py-C). (C) The location and local context of the most frequently 
mutated C residues along the IgV top strand in the gapped duplex and DT40 B cell mutation assays are compared. Mutation load at each nucleotide 
position is represented as a percentage of the total mutations in each dataset. (D) The percentages of total C mutations in the gapped duplex assays and 
DT40 B cells (top strand) at C residues with each of the four possible 5-flanking bases are compared for AID1 and AID1*/3G.146 Modifying AID alters IgV mutation spectrum | Wang et al.
Figure 5.  Mutation spectra from in vitro transcription-coupled mutation assays. (A) The T7-lacZ transcription-coupled substrate in which a T7 
promoter is inserted upstream of the lac promoter in M13mp19 (Fig. S5 B). Nucleotide position 1 is defined as the start of the lac promoter. The adjacent 
table shows the 5-flanking nucleotide preferences of the C mutations produced by GST-AID1 or GST-AID1*/3G in lac target DNA during in vitro transcrip-
tion by phage T7 RNA polymerase. (B) Mutation distribution along the T7 transcription-coupled lacZ target DNA with mutation at each nucleotide posi-
tion expressed as the percentage of total mutations. Two heavily mutated positions are off-scale: their percentage mutations are indicated. Because 
mutation analysis was restricted to Lac plaques, this selection results in a skewing in favor of lac-inactivating mutations, although most mutated tem-
plates carried 1–3 mutations in the target region. Positions at which C deamination yields a stop codon are indicated by an asterisk. (C) The location and 
local context of the five most frequently mutated C residues along the transcribed lac target. All the mutated residues shown are located on the top 
(nontranscribed) strand. (D) Transcription-linked mutation of a T7-linked GFP-V target. The substrate DNA is a derivative of plasmid pCR-Blunt II-TOPO 
in which a region of IgV (residues 115–164 or 228–263) has been inserted between the T7 promoter and a GFP reporter with T7-catalyzed transcription JEM VOL. 207, January 18, 2010 
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of the IgV fragment being in the same sense as IgV transcription in B cells (Fig. S5 C). For each construct (pCR-GFP-V115164-T7 and pCR-GFP-
V228263-T7), the tables compare the percentage of total mutations within the target V region that occur at selected individual positions with the 
equivalent percentage mutation values for the same positions over the same target regions in the M13 or B cell mutation assays. (E) Comparison of the 
mutation distributions obtained in the T7-coupled mutation assay over IgV residues 115–164 (for AID1) or 228–263 (for AID1*/3G) to the distributions 
obtained in DT40 B cells (left) or in the gapped duplex assay (right). In these comparisons, analysis is restricted to nontranscribed strand mutations.  
Positions of individual hotspots are indicated in italics. Red, 5-purine flank; blue, 5-pyrimidine flank.
 
(unpublished  data)  and  parallels  observations  in  previous 
work (Wang et al., 2009) that AID mutants displaying in-
creased specific activity are usually expressed at lower abun-
dance in B cell transfectants. The reason for this low expression 
is unclear but it might reflect cytotoxicity of excessive DNA 
deaminase activity.
In contrast to the AID/3C and AID/3F mutants, the 
AID1/3G mutant gave only a very low frequency of sIgM-
loss  variants.  However,  as  anticipated,  this  frequency  was 
considerably enhanced by deleting the AID C-terminal por-
tion (Fig. 3 A).
To characterize the IgV gene hypermutation spectrum in 
the DT40 B cell transfectants expressing the various modified 
AID proteins, the IgV segment from multiple independent 
transfectants for each expression construct was PCR ampli-
fied and sequenced after 8 wk of clonal expansion. The re-
sults reveal that the modifications of the AID active site result 
in a substantial alteration to the IgV mutation spectrum. 
Thus, AID/3C and AID1*/3G largely target C residues with 
a 5-flanking pyrimidine residue (68 and 75%, respectively) 
in contrast to the wild-type enzyme in which only 19% of 
the mutations are targeted to C residues with a 5-flanking 
pyrimidine (Fig. 3 B). This striking change in mutation spec-
trum is evident both in the composite datasets as well as in 
each of those from independent clones (Fig. 3 C). In contrast, 
AID/3F maintains the preference of the parental enzyme for 
a flanking purine residue, but (as found in the in vitro assay 
on the gapped duplex lacZ substrate; Fig. 2 B) there is a shift 
toward a preference for a flanking guanine rather than ade-
nine (Fig. 3 B).
The change in mutational targeting as judged by the na-
ture of the 5-flanking nucleotide broadly correlates with an 
altered mutational spectrum as judged by the distribution of 
nucleotide substitutions along the IgV segment (Fig. 3 D). 
Thus, for example, the IgV mutation hotspots are found at 
distinct  locations  when  comparing  wild-type  AID  with 
AID1*/3G.  With  wild-type  AID  (as  well  as  in  the  AID1 
upmutant; Fig. 3 D, Fig. S2, and Fig. S3), clusters of hotspots 
are evident within CDR1, toward the 5-side of CDR2 and 
also within CDR3, with these hotspots mostly conforming to 
a WRC consensus as observed previously (Sale et al., 2001; 
Arakawa et al., 2004; Saribasak et al., 2006; Wang et al., 2009). 
In contrast, the IgV mutations obtained using AID1*/3G 
show reduced clustering in CDR1 and CDR3, with a focus-
ing on hotspots with a 5-pyrimidine flank and which are 
located in regions (FR1 and FR3) that are relatively spared by 
the wild-type enzyme (Fig. 3 D and Fig. S3). Thus, changing 
the active site of AID modifies the mutation spectrum that is 
obtained both by DNA deamination in vitro and by antibody 
hypermutation in B cell transfectants.
Different hotspots dominate the B cell and in vitro 
mutation spectra
Although  the  active  site  modifications  in  AID/3C  and 
AID1*/3G have led to a shift from a preference for a flanking 
5-purine to a flanking 5-pyrimidine in both in vivo (DT40 
IgV) and in vitro (gapped-duplex lacZ) mutation assays, the 
nature of the shift in the two assays is not equivalent. Thus, 
for AID/3G, although T is the flanking pyrimidine of choice 
in the DT40 IgV mutation spectrum, a flanking C is pre-
ferred in the in vitro assay (Fig. 2 B and Fig. 3 B). This dis-
crepancy is substantially caused by the skewing effect of a few 
major hotspots in the DT40 IgV spectrum (Fig. 3 B), sug-
gesting that some aspect of hypermutation in B cells might 
result in the creation of dominant hotspots which are not re-
capitulated in the in vitro gapped duplex assay.
To confirm this, we performed the gapped duplex mu-
tation assay on an IgV (rather than lacZ) target sequence, 
comparing the resulting in vitro mutation spectrum to that 
observed  on  the  equivalent  (nontranscribed)  IgV  DNA 
strand in DT40 B cells (Fig. 4, A–D). Significant differences 
in mutational targeting are indeed observed; for example, 
compare the relative targeting in vivo and in vitro at V 
positions  126/141  or  336/348  with  wild-type  AID,  or 
compare targeting at 24/28/42 as well as at 241/242/252 
with AID1*/3G (Fig. 4 B). These differences are similarly 
evident if the highly mutated sequences are excluded from 
the database used to deduce the patterns of in vitro muta-
tional targeting.
To find out whether the differences in targeting could 
reflect that mutation in vivo likely occurs while transcribing 
double-stranded DNA, whereas the gapped duplex assay uses 
a  single-stranded  DNA  target,  we  investigated  mutational 
targeting using an assay described by Bransteitter et al. (2004) 
in which recombinant AID is incubated with double-stranded 
DNA at the same time as the target gene (lacZ) within the 
substrate is being transcribed from a linked T7 polymerase 
promoter. In such an assay, AID1*/3G clearly differs from 
wild-type AID, still preferring a 5-pyrimidine, especially 5-C, 
rather than the 5-T that is observed in DT40 B cells (Fig. 5, 
A–C). To assess mutational targeting within an IgV sub-
strate in an in vitro transcription-coupled assay, we modified 
the T7-linked assay to create a substrate in which unselected 
mutations in short segments of IgV can be scored in clones 
that have suffered mutational inactivation of a closely linked 
GFP reporter gene. However, in such assays we found that, as 148 Modifying AID alters IgV mutation spectrum | Wang et al.
Figure 6.  AID N51A mutants retain DNA deaminase activity. (A) Bacterial mutator activity of AID variants monitored by frequency of Rifr colonies 
in overnight cultures with mean frequencies (x108) from 12 independent cultures indicated. The N51A mutant of AID1 is abbreviated N51A1. (B) Switching  JEM VOL. 207, January 18, 2010 
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to IgG1 in LPS+IL-4 cultures of AID-deficient B cells that have been transduced with retroviruses encoding the various AIDs as indicated together with  
a linked IRES-GFP. Representative flow cytometry plots are presented along with histograms showing the results of four experiments (mean and SD,  
with 2–3 mice per construct per experiment). AID abundance in the B cell extracts 3 d after retroviral transduction was monitored by Western blotting; the 
blot was reprobed with anti-GFP antibodies as a control. (C) The frequency of surface IgM-loss variants in transfectants of AID/ V/ sIgM+ DT40 that 
coexpress the indicated AID mutant and GFP is presented both with a histogram showing the average percentage sIgM-loss variants in 12 independent 
clonal transfectants as well as by representative flow cytometry plots. Representative Western blots show AID abundance in the DT40 cell extracts with 
tubulin as loading control.
 
in the gapped duplex assay, we still did not recapture the rela-
tive dominance of major hotspots at IgV positions 141 (with 
wild-type AID) or 252 (with AID1*/3G) that was observed 
during hypermutation in DT40 cells (Fig. 5, D and E). In fact, 
the mutational targeting in the transcription-linked assay looks 
rather more similar to that obtained in the gapped duplex as-
say than to the pattern of mutational targeting observed in 
DT40 B cells. Thus, neither in vitro assay fully recapitulates 
the pattern of IgV hotspot dominance observed in B cells.
AIDs with altered target preference permit class switching
The preference of wild-type AID for a WRC (and especially 
AGCT) target sequence accords well with the sequence of the 
short consensus repeat in the S switch region (GAGCT). 
We were therefore interested to know whether the AID mu-
tants that preferred a 5-flanking pyrimidine would neverthe-
less retain the ability to trigger switching. Both AID/3C and 
AID/3F  were  able  to  potentiate  switching  after  retroviral 
transduction into LPS-activated AID-deficient B cells, although 
this occurred at a somewhat reduced efficiency (Fig. S4). The 
AID1/3G variant showed greatly reduced switching activity, 
but we cannot distinguish the extent to which this is caused 
by its altered target site preference as opposed to its reduced 
deaminase activity.
N51A mutation in AID reduces both DNA deamination  
and class switching
The finding that modifying AID’s active site such that it prefers 
a 5-flanking pyrimidine leads to corresponding change in the 
IgV gene mutation spectrum in B cells lends further strong 
support to the DNA deamination model of antibody diversifi-
cation. It is, however, difficult to reconcile with the claim that 
a single-point mutation (N51A) in AID can abolish its DNA 
deaminase activity while still allowing AID to retain 50% of its 
activity in class-switch recombination (Shivarov et al., 2008). 
We therefore decided to reexamine the effect of the N51A 
mutation on AID activity. In the context of human AID, the 
N51A mutation reduces the DNA deaminase activity of AID 
down to background as judged by the bacterial mutation assay 
(Fig. 6 A). However, we suspect that this mutation does not 
totally destroy AID activity. Mutator activity was still detected 
after introduction of the N51A substitution into our AID1 up-
mutant (which is substantially more active than wild-type AID 
as judged in the rifampicin resistance assay; Fig. 6 A). Never-
theless, neither AID[N51A] nor AID1[N51A] exhibited any 
detectable antibody diversification activity in either switching 
or somatic hypermutation assays (Fig. 6, B and C). Thus, the 
N51A mutation substantially reduces AID’s DNA deaminase 
activity (though probably not wholly destroying it) with the 
same mutant displaying a lack of detectable activity in antibody 
diversification assays. We therefore see no evidence in these 
experiments of CSR being triggered by an AID mutant lack-
ing DNA deaminase activity.
DISCUSSION
Altering the active site of AID such that it preferentially de-
aminates deoxycytidine residues in DNA that are flanked by 
a 5-pyrimidine (rather than purine) results in an analogous 
change in the IgV gene hypermutation spectrum in B cell 
transfectants. This provides strong support to the idea that the 
action of AID in antibody diversification in vivo involves its 
direct interaction with the DNA substrate.
The fact that by changing AID residues 115–123 it is 
possible to change the enzyme’s preference for 5-flanking 
nucleotide is in agreement with our earlier observations that 
target site preference changes (both in vitro and in vivo) also 
result from modifications in the equivalent region of APOBEC3 
deaminases (Langlois et al., 2005). Furthermore, the altered 
in vitro deamination specificity of our AID/3F and AID/3G 
enzymes coincides with the altered deamination preferences 
as analyzed by in vitro deamination assays of very similar AID 
variants that were recently described by Kohli et al. (2009). 
However, although the AID variants made by us and by Kohli 
et al. are very similar, they are not identical, which presum-
ably accounts for apparent minor differences in their catalytic 
activity/specificity.
Recent work in which it has been proposed that substitu-
tion of Asn51 by alanine in mouse AID results in loss of DNA 
deaminase activity, but retention of immunoglobulin class-
switching (Shivarov et al., 2008), is, however, clearly at odds 
with the DNA deamination model of antibody diversifica-
tion. We revisited the effect of the N51A substitution, but in 
the context of human AID, where we have previously gener-
ated upmutants that allow for more sensitive detection of 
DNA deaminase activity. In this context, we find that the 
N51A substitution causes a very substantial reduction (though 
not total ablation) of DNA deaminase activity and also results 
in a very substantial reduction in its ability to trigger class-
switching. We therefore do not consider that the previous 
results of Shivarov et al. (2008) indicate that AID’s function 
in antibody diversification is dissociated from its DNA deam-
inase activity, but instead believe that these authors’ results 
reflect differences in the dynamic ranges of the assays used for 
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strandedness, and therefore presumably have increased sus-
ceptibility to AID-catalyzed deamination; others have also 
predicted the formation of stable secondary structures cor-
relating with the intrinsic mutability of nucleotides at the 
CDRs during high levels of transcription (Wright et al., 
2008a, 2008b).
Nevertheless, we suspect that hotspot dominance might 
not simply be a function of local sequence but might also de-
pend on position within the transcription unit: hotspot dom-
inance is still evident in heterologous sequences that have 
been introduced into the Ig locus in place of the V segment 
(Yélamos et al., 1995). One possibility is that hotspot domi-
nance in vivo is affected by nucleosome phasing at the 5-end 
of the transcription unit. Indeed, recent work by Shen et al. 
(2009) provides compelling evidence that transcription plays 
a major role in allowing AID to act on chromatinized sub-
strates. It will be interesting in future work to extend on the 
approach pioneered by Shen et al. (2009) to ask whether it is 
possible to reproduce the in vivo pattern of IgV mutational 
hotspots in vitro using chromatinized targets with differently 
phased or modified nucleosomes or undergoing transcription 
by different transcription complexes; such studies could give 
valuable insights into the nature of the DNA substrate during 
antibody hypermutation in vivo.
Understanding the targeting of AID may not only give 
insight into the mechanism of creation of mutational hotspots 
in immunoglobulin genes, whose location appears to have 
been selected by coevolution of AID and the IgV gene tar-
get. One might also gain wider insights into the targeting 
of mutation during evolution. Thus, although many dis-
tinct mutagenic processes contribute to organismal evolu-
tion, AID-catalyzed DNA deamination provides a uniquely 
tractable system for experimental investigation. For example, 
the conclusions reached regarding the differential mutability 
of serine AGY and TCN codons in IgV gene SHM (Wagner 
et al., 1995) appear to also apply to their differential mutability 
of these two categories of serine codon during the genome 
evolution of organisms (Collins and Jukes, 1994). This is 
consistent with the suggestion of shared features between 
mutational targeting in SHM and in meiotic mutation (Oprea 
et al., 2001). Thus, studies of the effects of nucleosomes and 
nucleosome  phasing,  histone  modifications,  DNA-binding 
proteins, transcription, etc., on AID-dependent mutational 
hotspots could well give insight into wider aspects of muta-
tional targeting and genome evolution. The information could 
also be relevant to the study of off-target AID hotspots, for 
example, in protooncogenes with potential relevance to the 
creation of breakpoints for chromosomal translocations (Tsai 
et al., 2008).
The ability to alter the pattern of IgV gene mutational 
hotspots by altering the active-site of AID should also allow 
the creation of engineered mouse strains that display an al-
tered distribution of mutational hotspots within their IgV 
genes. It will be interesting to discover the effects of such an 
altered distribution on the efficiency of the maturation of 
high-affinity antibodies.
Although the active site of AID clearly plays a major 
role in determining the identity of the deamination targets 
acted upon, the hierarchy of target preferences of AID as 
judged by its in vitro action on single-stranded or transcrib-
ing double-stranded substrates does not recapture the de-
tailed pattern of AID-dependent hypermutation seen in   
B cells. Mutations are more evenly distributed among the 
various target C residues in the IgV in the in vitro assays as 
compared with IgV hypermutation in B cells, where domi-
nant hotspots can more readily be discerned (Fig. 4). Thus, 
the preferential focusing of SHM on the IgV CDR1 seen in 
previous studies (Betz et al., 1993a; Tomlinson et al., 1996) 
probably does not merely derive from the fact that CDR1 
contains a cluster of AID consensus target sequences. In-
deed, even with the AID/3G mutant that shows no affinity 
for WRC or CDR1 targets in in vitro DNA deamination 
assays, circumstances in B cells nevertheless appear to en-
courage a small amount of mutation accumulation in CDR1 
(Fig. 3 D and Fig. 4 B).
What could be responsible for these differences in the 
mutational targeting at the IgV observed when comparing 
the B cell hypermutation and in vitro deamination assays? 
Although there could be a contribution from differential 
DNA repair, this is unlikely to be the sole explanation be-
cause the mutation spectrum in the in vitro assays is exam-
ined after transformation into E. coli cells deficient in the 
uracil-DNA glycosylase repair enzyme; previous work has 
also revealed that dominant IgV gene mutational hotspots 
observed during hypermutation in normal B cells are still 
evident in repair-deficient B cells (Di Noia and Neuberger, 
2002; Rada et al., 2004; Saribasak et al., 2006; Shen et al., 
2006). A distinct possibility is that part of the difference 
might be caused by some posttranslational modification of 
AID that occurs in B cells, but is not present on the recom-
binant AID used in our in vitro assays. Indeed, the detailed 
target preference of AID has been shown to be affected (at 
least in vitro) by single amino acid substitutions at serine 38 
(Pham et al., 2008), a residue known to undergo phosphor-
ylation in vivo (Basu et al., 2005). We suspect, however, 
that an even greater responsibility is likely to lie in a differ-
ence of the nature of the DNA targets analyzed in vitro and 
in vivo. The former consists of single- or transcribing double-
stranded naked DNA; the latter is likely to be in transcrip-
tionally active chromatin.
Although  evolutionary  selection  could  well  have  fa-
vored the emergence of hotspots at selected positions within 
the IgV to assist antibody maturation, such selection would 
presumably not contribute in noncoding flanking sequences. 
Consistent with this, a recent analysis by MacCarthy et al. 
(2009) of mutation accumulation in the JH 3-flank did not 
reveal the same degree of discrepancy between in vivo and 
in vitro mutation spectra that we observe here within the 
body of IgV. What then could be the molecular mecha-
nisms contributing to hotspot dominance within the IgV 
region in vivo? Ronai et al. (2007) have detected regions 
within the IgV in vivo that exhibit increased local single-JEM VOL. 207, January 18, 2010 
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from dynastically related sequences, identical mutations in sequences from 
a single B cell culture that shared more than one common mutation were 
computed only once.
To assay class-switching, surface IgG1 expression was analyzed by flow 
cytometry in B cells that had been purified from AID/ mice and cultured 
in the presence of LPS+IL-4 (48 h) after a 24-h infection with AID-encoding 
retroviruses, as previously described (Geisberger et al., 2009). The abundance 
of AID in extracts prepared by heating 106 cells in 50 µl of reducing SDS-
sample buffer was monitored following SDS-PAGE by Western blot analysis 
using rabbit anti-AID antiserum (Abcam); GFP was detected using HRP 
conjugated goat anti-GFP antiserum (Abcam); tubulin was detected using 
mouse antitubulin antibody (Abcam).
Online supplemental material. Fig. S1 shows an analysis of the semipuri-
fied GST-AIDs on SDS/PAGE, provides information on the mutation loads 
produced by them in the lacZ gapped-duplex assay, and compares the spec-
trum of AID1/3G and AID1*/3G to show that the C-terminal truncation 
does not affect the pattern of in vitro mutational targeting. Fig. S2 shows a 
comparison of the IgV mutation spectrum in DT40 transfectants expressing 
wild-type AID or AID1. Fig. S3 provides a compilation of the IgV muta-
tions identified in DT40 cells expressing the various modified AID proteins. 
Fig. S4 presents the results of class-switching assays performed with modified 
AID proteins. Fig. S5 provides the DNA sequences of the various substrates 
used in the in vitro DNA deamination assays. Online supplemental material 
is available at http://www.jem.org/cgi/content/full/jem.20092238/DC1.
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MATERIALS AND METHODS
Rifampicin  resistance  assay.  E.  coli  strain  KL16  (Hfr  [PO-45]  relA1 
spoT1 thi-1) transformed with pTrc99/AID plasmids was grown overnight 
to saturation in LB medium supplemented with ampicillin (100 µg ml–1) 
and isopropyl -D-1-thiogalactopyranoside (IPTG; 1 mM), and plated on 
LB low-salt agar containing ampicillin (100 µg ml–1) and rifampicin (50 µg 
ml–1).  Mutation  frequencies  were  measured  by  determining  the  median 
number of colony-forming cells that survived selection per 107 viable cells 
plated with each median determined from 12 independent cultures. The 
identity of mutations was determined by sequencing the relevant section 
of rpoB (typically from 25 to 200 individual colonies) after PCR amplifica-
tion using oligonucleotides 5-TTGGCGAAATGGCGGAAAACC-3 and 
5-CACCGACGGATACCACCTGCTG-3).
Assaying deaminase target specificity in vitro. For assay on a gapped 
duplex substrate, a 475-nt single-stranded gap in M13mp19 DNA was 
generated by annealing replicative form M13mp19 DNA that had been 
digested with PvuII and BglI to single-stranded M13mp19 DNA ex-
tracted from phage as previously described (Bebenek and Kunkel, 1995). 
Deamination of this gapped substrate (0.5 µg) by GST-AID fusion pro-
tein (200 ng; semipurified as previously described; Wang et al., 2009) 
was monitored at 37°C in 10 µl reaction buffer (8 mM-Tris, pH 8.0,   
8 mM-KCl, 10 mM-NaCl, 2.5 mM-EDTA, and 0.2 mM-dithiothreitol) 
containing 0.5 µg µl–1 RNase A essentially as described by Pham et al. 
(2003). Deamination reactions were terminated by diluting samples to 
100 µl with water and, after phenol extraction, the DNA was transfected 
into E. coli strain BD1528 F– (codB-lacI)3 ung-1 hsdR514) and plated to-
gether with -complementation E. coli strain TG1 (supE thi-1 ∆(lac-proAB)   
hsd∆5 [F´traD36 proAB+ lacIq Z∆M15]), Xgal (0.8 mg ml–1), and IPTG   
(80 µg ml–1) onto minimal glucose agar. DNA from white or light blue 
plaques  was  sequenced  using  primers  5-GCAAACCAGCGTGGACC-
GCTTGC-3  (forward)  and  5-GGACGACGACCGTATCGGCCT-
CAG-3 (reverse). Mutations were analyzed using Sequencher software 
(Gene Codes Corporation).
For the T7 transcription-coupled assays, semipurified GST-AID (200 ng) 
was incubated with 1 µg DNA substrate (either M13mp19, in which a 
27-nt fragment containing the T7 promoter had been inserted upstream of 
lacZ [Fig. S5 B], or plasmid pCR-Blunt II-Topo (Invitrogen), in which a 
GFP gene and either 49- or 35-nt fragments [positions 115–164 or 228–263] 
of chicken IgV were placed between the lac and T7 promoters [Fig. S5C]) 
at 37°C in 10 µl reaction buffer (40 mM-Tris, 6 mM-MgCl2, 10 mM- 
dithiothreitol, and 2 mM-spermidine, pH 7.9) containing RNase A (0.5 µg 
µl–1), 0.6 mM rNTP mix and 2 U T7 RNA polymerase (NEB). For the 
M13mp19-T7-lacZ transcription substrate, the extraction and visualization 
of mutated DNA products were as described for the gapped duplex assay. 
For the pCR-Topo-T7-V-GFP reporter substrates, the extracted DNA 
products were transformed into BD1528, plated onto TYE plates supple-
mented with 50 µg ml–1 kanamycin, and incubated at 37°C until colonies 
turned green. DNA from colorless colonies was sequenced as described for 
the gapped duplex assay.
Assaying antibody diversification. AID-induced SHM was monitored 
by measuring the frequency of sIgM-loss variants in AID/ V/ sIgM+ 
DT40 cells transfected with AID-encoding vectors based on pExpressPuro2 
(Arakawa et al., 2004) in which AID and GFP transcription units are coex-
pressed from a vector including a puromycin-resistance cassette (gift from 
J.-M. Buerstedde, Institute of Molecular Radiobiology, Munich, Germany). 
For each construct, the percentage of sIgM– cells was monitored in 8–12 
independent transfectants that had been expanded under selection (0.5 µg 
ml–1 puromycin) for 3 wk before flow cytometry. After 8 wk of culturing, 
mutations in the IgV region were characterized by sequencing genomic 
DNA that was PCR-amplified from either 100,000 unsorted or (GFP+, 
sIgM–)-sorted cell equivalents (forward 5-CAGGAGCTCGCGGGGCC-
GTCACTGATTGCCG-3; reverse 5-GCGCAAGCTTCCCCAGCCT-
GCCGCCAAGTCCAAG-3). To minimize double counting of mutations 152 Modifying AID alters IgV mutation spectrum | Wang et al.
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